Results per Page:
A moving target: How spike’s shape determines immune escape in SARS-CoV-2
From the Bloom Lab, Basic Sciences Division
Data-driven enrollment for COVID-19 vaccine clinical trials
From the HIV Vaccine Trials Network/COVID-19 Prevention Network
RR tracks: a new way to measure viral transmission
From the Bedford Lab, Vaccine and Infectious Disease, Public Health and Human Biology Divisions
Natural born killers: harnessing innate immunity to fight severe infections
From the Joshua Hill lab, Vaccine and Infectious Disease Division
COVID watchdawgs: SARS-CoV-2 at UW in the pandemic’s early days
From the Chu and Weil Labs, UW Medicine, in collaboration with the Cancer Basic Biology Program of the Cancer Consortium and Fred Hutch Vaccine and Infectious Disease Division
Identificación de anticuerpos potentes y ampliamente neutralizantes contra los sarbecovirus, incluidos el SARS-CoV-1 y el SARS-CoV-2
Del Laboratorio Overbaugh, División de Biología Humana
Drs. Keith Jerome and Jesse Bloom elected fellows of American Academy of Microbiology
Fred Hutch researchers’ study of viruses evolves from basic understanding to practical applications
With respiratory infections rampant, experts urge masking and vaccination
Limited disease data makes it hard to accurately assess flu trends
Identification of potent and broadly-neutralizing antibodies against sarbecoviruses including SARS-CoV-1 and SARS-CoV-2
From the Overbaugh lab, Human Biology Division
Crunching the numbers for next-gen COVID-19 vaccines
BARDA taps Fred Hutch biostatisticians to assess new vaccine technology, more nimble trial design
¿Necesito otra vacuna de refuerzo contra el SRAS-CoV-2?
Del Dr. Bo Zhang y laboratorios colaboradores, División de Vacunas y Enfermedades Infecciosas
Long COVID: key risk factors in postmenopausal women
From the Neuhouser research group, Public Health Sciences Division
Do I need another SARS-CoV-2 booster vaccine?
From Dr. Bo Zhang and collaborating labs, Vaccine & Infectious Disease Division
A new era of COVID-19 brings new outlooks for cellular therapy recipients
From the Liu Group, Vaccine and Infectious Disease Division
The exclusion of immunocompromised patients in clinical trials and how we can do better
From Drs. Michael Boeckh, Joshua Hill, Steven Pergam and Larry Corey, Hematologic Malignancies and Cancer Immunology Programs of the Cancer Consortium
A method to predict how a virus might spread through a population
From the Bedford Lab, Vaccine and Infectious Disease Division
Dedicated supporters at the Heart of the Hutch
Using creativity and passion to support Fred Hutch research in good times and bad
SARS-CoV-2 vaccine efficacy in Latin American countries
From the Gilbert Group, Vaccine and Infectious Disease and Public Health Sciences Divisions